Skip to main content
Premium Trial:

Request an Annual Quote

Strategic Diagnostics' Antibody Revenue Gains Tempered by Ag/GMO Decline

NEW YORK (GenomeWeb News) — Strategic Diagnostics today said third-quarter revenues were flat as R&D spending rose 9 percent and profit fell around 70 percent.
Total receipts for the three months ended Sept. 30 dipped slightly to $6.56 million from $6.62 million year over year.
The company said antibody revenues rose 15.2 percent over the quarter from $3.1 million to $3.6 million, and accounted for nearly 55 percent of total revenue. Strategic Diagnostics' food pathogen detection sales rose 22.6 percent to $1.1 million.
These revenue gains were offset by a nearly 50 percent drop in sales from the company's legacy US Ag/GMO business year-over-year.
Strategic Diagnostics’ R&D spending rose to $723,000 from $666,000 million year over year.
The company said third-quarter profit shrank to $100,000 from $332,000 in the year-ago period.
Strategic Diagnostics finished the quarter with around $11.9 million in cash and cash equivalents.
The company did not offer revenue predictions for full-year 2007.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.